HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress

Reuters

Oct 13

HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress

HUTCHMED (China) Ltd. announced that data from the FRUSICA-2 registration trial, evaluating the combination of fruquintinib and sintilimab in patients with advanced renal cell carcinoma who have progressed after first-line therapies, will be presented at the 2025 ESMO Congress. The combination has demonstrated significant improvements in progression-free survival in this patient population. Results from the study have not yet been presented and will be disclosed at the upcoming congress. Fruquintinib, in combination with sintilimab, has conditional approval in China for the treatment of advanced pMMR endometrial cancer in patients who have failed prior systemic therapy and are not candidates for curative surgery or radiation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575457425"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575457425\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575457425?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 12:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575457425","market":"nz","top_or_hot":-1,"title":"HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HUTCHMED (China) Ltd. announced that data from the FRUSICA-2 registration trial, evaluating the combination of fruquintinib and sintilimab in patients with advanced renal cell carcinoma who have progressed after first-line therapies, will be presented at the 2025 ESMO Congress. The combination has demonstrated significant improvements in progression-free survival in this patient population. Results from the study have not yet been presented and will be disclosed at the upcoming congress. Fruquintinib, in combination with sintilimab, has conditional approval in China for the treatment of advanced pMMR endometrial cancer in patients who have failed prior systemic therapy and are not candidates for curative surgery or radiation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-13 12:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HUTCHMED (China) Ltd. announced that data from the FRUSICA-2 registration trial, evaluating the combination of fruquintinib and sintilimab in patients with advanced renal cell carcinoma who have progressed after first-line therapies, will be presented at the 2025 ESMO Congress. The combination has demonstrated significant improvements in progression-free survival in this patient population. Results from the study have not yet been presented and will be disclosed at the upcoming congress. Fruquintinib, in combination with sintilimab, has conditional approval in China for the treatment of advanced pMMR endometrial cancer in patients who have failed prior systemic therapy and are not candidates for curative surgery or radiation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL2ngkDW:1","article_id":"2575457425","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575457425","pubTimestamp":1760328199,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress. HUTCHMED  Ltd. announced that data from the FRUSICA-2 registration trial, evaluating the combination of fruquintinib and sintilimab in patients with advanced renal cell carcinoma who have progressed after first-line therapies, will be presented at the 2025 ESMO Congress. The combination has demonstrated significant improvements in progression-free survival in this patient population. Results from the study have not yet been presented and will be disclosed at the upcoming congress. Fruquintinib, in combination with sintilimab, has conditional approval in China for the treatment of advanced pMMR endometrial cancer in patients who have failed prior systemic therapy and are not candidates for curative surgery or radiation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1588":"回港中概股","00013":"和黄医药","BK1191":"制药","BK1587":"次新股"},"translate_title":"和黄医药宣布呋喹替尼和信迪利单抗组合治疗晚期肾细胞癌的FRUSICA-2试验结果积极；数据将在2025年ESMO大会上公布","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":0.9},"content_text":"HUTCHMED Announces Positive FRUSICA-2 Trial Results for Fruquintinib and Sintilimab Combo in Advanced Renal Cell Carcinoma; Data to Be Presented at 2025 ESMO Congress\n    \n\n        HUTCHMED (China) Ltd. announced that data from the FRUSICA-2 registration trial, evaluating the combination of fruquintinib and sintilimab in patients with advanced renal cell carcinoma who have progressed after first-line therapies, will be presented at the 2025 ESMO Congress. The combination has demonstrated significant improvements in progression-free survival in this patient population. Results from the study have not yet been presented and will be disclosed at the upcoming congress. Fruquintinib, in combination with sintilimab, has conditional approval in China for the treatment of advanced pMMR endometrial cancer in patients who have failed prior systemic therapy and are not candidates for curative surgery or radiation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}